Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep 1;25(9):3073-3079.
doi: 10.31557/APJCP.2024.25.9.3073.

Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study

Ehab Saad  1 , Mohamed Abdulla  1 , Amr Nassef  2 , Nadia Ebrahim  1 , Rabab Abdel Moneim  1
Affiliations
Randomized Controlled Trial

Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study

Ehab Saad et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Both Stereotactic Body Radiation Therapy (SBRT) and Trans-arterial Chemoembolization (TACE) are now being widely used to treat advanced hepatocellular carcinoma (HCC) and can improve tumor local control rates. We aimed at evaluating the efficacy and toxicity of combining SBRT and TACE in comparison to TACE alone in unresectable HCC.

Methods: 42 unresectable Barcelona Clinic Liver Cancer (BCLC) stage B HCC Child Pugh (CP) A patients were randomized to receive either: TACE alone (Arm A) or TACE followed by SBRT (Arm B). Dose prescribed was 40Gy in 5consecutive daily fractions over 1 week . We compared the local control (LC), Progression free survival (PFS), overall survival (OS) and toxicity between the two arms.

Results: 22 patients were in arm A versus 20 patients in arm B with median follow up 20 months starting recruitment from April 2021 till January 2023. Both LC, PFS were significantly better in Arm B. Complete remission (CR) rate was 54.5% and 75% in Arm A and B, respectively. Median PFS was 16 months in Arm B compared to 11 months in Arm A (p =0.003). Median OS was not reached in both arms. Both arms had comparable toxicities.

Conclusion: Adding SBRT to TACE in advanced HCC, is safe and feasible with better efficacy in terms of LC and PFS with comparable side effects, in comparison to TACE alone.

Keywords: Stereotactic Body Radiation therapy( SBRT); Transarterial chemoembolization (TACE); hepatocellular carcinoma (HCC).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier Curve Showing Progression Free Survival among Studied Groups.
See this image and copyright information in PMC

References

    1. Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M, et al. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2018;9(4):734–40. - PMC - PubMed
    1. Elkenawy I, Elbendary M, El-Gilany A-H, Shabana W. Characteristics of hepatocellular ‎carcinoma in egyptian patients : ‎a single center pilot study. Afro-Egyptian Journal of Infectious and Endemic Diseases. 2022:402–9.
    1. Seif El Dahan K, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, et al. Multidisciplinary care for patients with hcc: A systematic review and meta-analysis. Hepatol Commun. 2023;7:5. - PMC - PubMed
    1. Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2023;11(2):480–9. - PMC - PubMed
    1. Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, et al. The modified response evaluation criteria in solid tumors (recist) yield a more accurate prognoses than the recist in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver. 2020;14(6):765–74. - PMC - PubMed

Publication types